182 related articles for article (PubMed ID: 20095973)
21. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.
Gerner EW; Ignatenko NA; Lance P; Hurley LH
Ann N Y Acad Sci; 2005 Nov; 1059():97-105. PubMed ID: 16382048
[TBL] [Abstract][Full Text] [Related]
23. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
24. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
Nicastro HL; Grubbs CJ; Margaret Juliana M; Bode AM; Kim MS; Lu Y; You M; Milne GL; Boring D; Steele VE; Lubet RA
Cancer Prev Res (Phila); 2014 Feb; 7(2):246-54. PubMed ID: 24346344
[TBL] [Abstract][Full Text] [Related]
25. Polyamines as modifiers of genetic risk factors in human intestinal cancers.
Babbar N; Gerner EW
Biochem Soc Trans; 2003 Apr; 31(2):388-92. PubMed ID: 12653645
[TBL] [Abstract][Full Text] [Related]
26. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
28. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
29. Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC.
Faux MC; Weinstock J; Gogos S; Prato E; Azimpour AI; O'Keefe R; Cathcart-King Y; Garnham AL; Ernst M; Preaudet A; Christie M; Putoczki TL; Buchert M; Burgess AW
Cancer Res Commun; 2022 Feb; 2(2):66-77. PubMed ID: 36860494
[TBL] [Abstract][Full Text] [Related]
30. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
Reddy BS; Nayini J; Tokumo K; Rigotty J; Zang E; Kelloff G
Cancer Res; 1990 May; 50(9):2562-8. PubMed ID: 2109653
[TBL] [Abstract][Full Text] [Related]
32. Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Yang L; Wang Y; Hu S; Wang X
Front Oncol; 2023; 13():1281844. PubMed ID: 38033490
[TBL] [Abstract][Full Text] [Related]
33. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
Kadmon D
J Cell Biochem Suppl; 1992; 16H():122-7. PubMed ID: 1289667
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
36. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
37. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats.
Madka V; Patlolla JMR; Venkatachalam K; Zhang Y; Pathuri G; Stratton N; Lightfoot S; Janakiram NB; Mohammed A; Rao CV
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568816
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
40. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Simoneau AR; Gerner EW; Nagle R; Ziogas A; Fujikawa-Brooks S; Yerushalmi H; Ahlering TE; Lieberman R; McLaren CE; Anton-Culver H; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):292-9. PubMed ID: 18268112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
